Dr.Reddy's Laboratories said that US FDA has classified the inspection at formulations manufacturing plant at Duvvada, Visakhapatnam, as "voluntary action initiated" (VAI).
The scrip advanced 0.45% to Rs 3322.50. It traded in the range of Rs 3312 and Rs 3332.35 so far during the day.
A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, the FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
Dr Reddy's Laboratories offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major markets include - USA, India, Russia & CIS countries, and Europe.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
